Embed Size (px)
DESCRIPTION
Renub Research has announced the addition of the "Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global" report to its offering
Citation preview
Hepatitis C Market & Forecast, Hepatitis C Pipeline
Drugs Sales & Forecast, Clinical Trials - Global
Renub Researchwww.renub.com
Published: August, 2015Copyright © 2015 Renub Research – All Rights Reserved
Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in
the year 2014 compared to 2013. In the last two years a couple of new drugs have been
introduced in the market which has become a huge success and they have captured maximum
market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar
Hepatitis C market, but AbbVie has been trying to increase its market share since U.S.
regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on
introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C
Drugs is anticipated to be a rosy market for future period.
This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled
“Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales
& Forecast - Global” provides a comprehensive assessment of the fast-evolving, high-growth of
Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug
Market Landscape.
1. Hepatitis C Drugs Market & Forecast (Chapter 2)
2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
3. Hepatitis C – Pipeline Drugs Sales & Forecast (Chapter 4)
4. Hepatitis C Deals & Acquisitions (Chapter 5)
5. Hepatitis C – Company Wise Clinical Trial Analysis (Chapter 6)
Hepatitis C – Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
5. Olysio
6. Sovaldi/Harvoni
7. HCV Franchise
8. Viekira Pak
© Renub Research Page 3 of 12
Hepatitis C – Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)
1. Drug A (Merck & Co. Inc.)
2. Drug B (Merck & Co. Inc.)
3. Drug C (Bristol-Myers Squibb)
Hepatitis C – Company Wise Clinical Trial Analysis (Chapter No.5)
1. AbbVie
2. Bristol-Myers Squibb (BMS)
3. Gilead Sciences
4. Merck & Co. Inc.
5. Tibotec/Janssen Therapeutics
Data Sources
This report is built using data and information sourced from proprietary databases, primary and
secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-
printable sources like search engines, News websites, Government Websites, Trade Journals,
White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books,
Industry Portals, Industry Associations and access to more than 500 paid databases.
© Renub Research Page 4 of 12
About Us
RReennuubb RReesseeaarrcchh is a leading Market Research and Information Analysis Company with
centers at Noida India and Roswell USA. We have long-term experience especially in
international Business-to-Business Researches, Surveys, Business and Consulting. Throughout
the years we have acquired expertise in most market sectors, including Information Technology
(IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking,
Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer
Goods, Logistics, Governmental, Social, and Others.
Our core team is comprised of an experienced people holding graduate, post graduate and
Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information
Technology, Environmental Science and many more. Our research help make the business
decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We
support many blue chip companies by providing them findings and perspectives across a wide
range of markets. Our research reports offer a blend of information insight, analysis and
forecasting that is essential in today’s ultra-competitive markets.
For more information on us or to view any of our sample work you can mail
us at [email protected]
© Renub Research Page 5 of 12
Published
By
RReennuubb RReesseeaarrcchh
1st Floor,
C – 86, Sector - 10
Noida – 201301
Phone: +91-120-421-9822, 254-5750 (India)
+1-678-302-0700 (USA)
Fax : +91-120-424-9780
Email: [email protected]
www.renub.com
© Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales
& Forecast - Global
Renub Research, 2015
Edition 3.0
All rights reserved. This publication is protected
by copyright. No part of it may be reproduced, stored
in a retrieval system or transmitted, in any form or by
any means, electronic mechanical, photocopying,
recording or otherwise without the prior written
permission of the publishers
© Renub Research Page 6 of 12
Table of Contents
1. Executive Summary
2. Hepatitis C Drugs – Market & Forecast
3. Hepatitis C – Approved Drugs Sales & Forecast
3.1 Pegasys Sales & Forecast
3.2 Pegintron Sales & Forecast
3.3 Incivek Sales
3.4 Victrelis Sales & Forecast
3.5 Olysio Sales & Forecast
3.6 Sovaldi / Harvoni Sales & Forecast
3.7 HCV Franchise Sales & Forecast
3.8 Viekira Pak Sales & Forecast
4. Hepatitis C - Pipeline Drugs Sales Forecast
4.1 Drug A of (Merck & Co. Inc.)
4.2 Drug B of (Merck & Co. Inc.)
4.3 Drug C of (Bristol-Myers Squibb)
5. Hepatitis C – Deals & Acquisitions
6. Hepatitis C – Company Wise Clinical Trials Analysis
6.1 AbbVie – Clinical Trials
6.1.1 Phase III
6.1.2 Phase II
6.1.3 Phase I
6.2 Bristol-Myers Squibb (BMS) – Clinical Trials
6.2.1 Phase III
© Renub Research Page 7 of 12
6.2.2 Phase II
6.3 Gilead Sciences – Clinical Trials
6.3.1 Phase II
6.4 Merck & Co. Inc. – Clinical Trials
6.4.1 Phase IV
6.4.2 Phase III
6.4.3 Phase II
6.4.4 Phase I
6.5 Tibotec / Janssen Therapeutics – Clinical Trials
6.5.1 Phase IV
6.5.2 Phase III
6.5.3 Phase II
6.5.4 Phase I
© Renub Research Page 8 of 12
List of Figures:
Figure 2-1: Global – Hepatitis C Drug Market (Million US$), 2010 – 2014
Figure 2-2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2015 – 2020
Figure 3-1: Global – Pegasys Sales (Million US$), 2005 – 2014
Figure 3-2: Global – Forecast for Pegasys Sales (Million US$), 2015 – 2020
Figure 3-3: Global – Pegintron Sales (Million US$), 2010 – 2014
Figure 3-4: Global – Forecast for Pegintron Sales (Million US$), 2015 – 2020
Figure 3-5: Global – Incivek Sales (Million US$), 2011 – 2014
Figure 3-6: Global – Victrelis Sales & Forecast (Million US$), 2011 – 2015
Figure 3-7: Global – Olysio Sales (Million US$), 2013 – 2014
Figure 3-8: Global – Forecast for Olysio Sales (Million US$), 2015 – 2020
Figure 3-9: Global – Sovaldi/Harvoni Sales (Million US$), 2013 – 2014
Figure 3-10: Global – Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 – 2020
Figure 3-11: Global – HCV Franchise Sales & Forecast (Million US$), 2014 – 2020
Figure 3-12: Hepatitis C Drugs – Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
Figure 3-13: Global – Viekira Pak Sales & Forecast (Million US$), 2014 – 2020
Figure 4-1: Global – Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 – 2020
Figure 4-2: Global – Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 –
2020
Figure 4-3: Global – Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 – 2020
© Renub Research Page 9 of 12
List of Tables:
Table 5-1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012
© Renub Research Page 10 of 12
Order Form
Scan and e-mail this page to [email protected], alternatively one can also write the Contact
Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780
Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to
Format
Report Title: Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast,
Clinical Trials – Global
Single User (Email from Publisher)
Hard Copy (Mail Delivery)
CD – Rom (Mail Delivery)
Global Site License (Multiple User License)
US$ 1290 US$ 1440 US$ 1390 US$ 2090
For ordering this report: Easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.):
http://www.renub.com/hepatitis-c-market-and-forecast-hepatitis-c-pipeline-drugs-sales-and-
forecast-clinical-trials-global-466-p.php
© Renub Research Page 11 of 12
Bank Details
Account Name: Renub Research
A/C No.: 109102000023296
Name of Bank: IDBI Bank Ltd.
Swift Code: IBKLINBB010
Bank Address: 4th Floor
Indian Red Cross Building
1 Red Cross Road
Opposite Parliament Street
New Delhi – 110001
India
Contact Information
First Name: Last Name:
Email:
Job Title:
Company:
Address:
City:
Postal/Zip Code:
Country:
Phone:
Mobile:
Fax:
Report Format:
Your message:
© Renub Research Page 12 of 12
3) Order by Check
Please post the check accompanied by this form, to:
Company Address: Renub Research
1st Floor
C-86, Sector -10
Noida - 201301
Uttar Pradesh
India
Phone: +91-120-421-9822, 424-9780
For free Sample copy report or to view any of our sample work please contact us at
[email protected] or call +91-120-421-9822 (India), +1-678-302-0700 (USA)
Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090
LinkedIn: http://www.linkedin.com/company/renub-research
Twitter: http://twitter.com/RenubResearch
